Dayu Shi

Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation

Jing-Rui Zhou, Dayu Shi, Rong Wei et al. · Frontiers in Immunology · 2021 · 37 citations · Full text

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Qian Jiang, Xiao‐Jun Huang, Zi Chen et al. · Blood · 2019 · 27 citations

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, Xiao‐Jun Huang, Zi Chen et al. · Blood · 2020 · 25 citations

Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Dayu Shi, Zongru Li, Yongjie Li et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 18 citations

Psychological Co-morbidities, Psychopathology, Mental Health +16

Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)

Qian Jiang, Dayu Shi, Zongru Li et al. · Blood · 2021 · 12 citations